Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: An Australian multicentre experience

ANZ Journal of Surgery

Volumn 74, Issue 11, 2004, Pages 951-956

  Hughes, Brett G M ^a   Yip, Desmond ^a   Chao, Michael ^b   Gibbs, Peter ^b   Carroll, Susan ^c   Goldstein, David ^c   Burmeister, Bryan ^d   Karapetis, Christos ^e  

^a CANBERRA HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Adenocarcinoma; Combined modality therapy; Gastrectomy; Stomach neoplasm

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; AUSTRALIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL AUDIT; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; STOMACH TUMOR; TIME;

ADENOCARCINOMA; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; POSTOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TIME FACTORS;

EID: 16644371714     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-1433.2004.03218.x     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001; 94: 153-156
2. Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR). Cancer in Australia 2000. Canberra: AIHW, 2003.
3. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001; 345: 725-730 (Pubitemid 34936653)
4. Macdonald J, Smalley S, Benedetti J et al. Postoperative Combined Radiation and Chemotherapy Improves Disease-Free Survival (DFS) and Overall Survival (OS) in Resected Adenocarcinoma of the Stomach and G.E. Junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc. Am. Soc. Clin. Oncol. 2000; 19: Abstract 1.
5. Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 1994; 5: 609-616 (Pubitemid 24283097)
6. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 1993; 11: 1441-1447 (Pubitemid 23228247)
7. Hermans J, Bonenkamp H. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal (correspondence). J. Clin. Oncol. 1993; 12: 877-880
8. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer 1999; 86: 1657-1668 (Pubitemid 29513033)
9. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. 1999; 340: 908-914
10. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 1999; 79: 1522-1530 (Pubitemid 29116815)
11. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1357-1362
12. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br. J. Surg. 2000; 87: 236-242 (Pubitemid 30088655)
13. Macdonald J, Smalley S, Benedetti J et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). Proc. Am. Soc. Clin. Oncol. GI Cancer Symp. 2004; 1.
14. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J. Surg. 1988; 75: 110-112
15. Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001; 129: 103-109 (Pubitemid 32099263)
16. Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br. J. Cancer 2002; 86: 1223-1229 (Pubitemid 34888171)
17. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc. Am. Soc. Clin. Oncol. 2003; 22: Abstract 998.
18. Cunningham D, Allum W, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial of the UK NCRI Upper GI Clinical Studies Group (the MAGIC trial, ISRCTN 93793971). Eur. J. Cancer Suppl. 2003; 1: S18.
19. Arias de la Vega F, Vera R, Domínguez M et al. Chemoradiotherapy after surgery for adenocarcinoma of the stomach. Final results of a prospective, phase II, single-institutional program. Eur. J. Cancer Suppl. 2003; 1: S65.
20. Park SH, Kim DY, Heo JS et al. Postoperative chemoradiotherapy for gastric cancer. Ann. Oncol. 2003; 14: 1373-1377
21. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. Br. J. Cancer 1999; 80: 269-272 (Pubitemid 29210117)
22. Leong T, Michael M, Foo K et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br. J. Cancer 2003; 89: 1433-1438 (Pubitemid 37390854)
23. Budach W, Hehr T, Kollmannsberger C et al. Adjuvant chemoradiotherapy with 5FU/FA/DDP/paclitaxel in locally advanced gastric cancer (UICC II-IV, M0). Eur. J. Cancer Suppl. 2003; 1: S71.